https://www.selleckchem.com/pr....oducts/gsk1120212-jt
Differential efficacy of newly registered therapies in subgroups of metastatic breast cancer (MBC) is an important consideration for subsequent use in clinical practice. Unfortunately, such subgroup analyses often are exploratory and rarely statistically adequately powered and may thus be misleading. This analysis aimed to explore a potentially different treatment response to i.v. therapies between visceral and non-visceral MBC. In a systematic literature analysis (PubMed) comprising phase III registration studies for MBC f
Like
Comment
Share
